A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
Breast Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 71 (final count)
- Started
- Feb 19, 2024
- Main results expected
- Sep 5, 2025
- Fully finished
- May 25, 2027
- Results posted
- Sep 30, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants With Dose-Limiting Toxicities (DLTs): Phase 1b
Measured over: Cycle 1 (28 days)
Percentage of Participants With Confirmed Objective Response (OR) by Derived Investigator Assessment: Phase 2
Measured over: From the date of first dose of study treatment combination until the first documentation of disease progression (PD), death or start of new anticancer therapy, whichever occurred first (maximum treatment exposure of 9.5 months for Phase 2)
Changes Tremor has spotted
Paperwork edit (contacts, locations, wording). Usually harmless.
Spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- 2026-11-06 15:29 UTC · paperwork · other
old: null
new: null
details: {"sections":["referencesModule"]}
Trial ID NCT06206837 · record last updated 2026-09-30 · checked 2026-11-09 15:36 UTC